Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM)

Mastocytosis is a rare clonal disorder of mast cells, manifestations of which are protean and can include anaphylaxis, urticaria/angioedema, malabsorption, and osteoporosis. Although there is no known cure, treatments include antimediator medications and cytoreductive therapy.1 More recent treatments include agents targeting the commonly associated mutations in the KIT receptor (CD117), but these can have significant adverse effects.2